Genelux Stock (NASDAQ:GNLX)
Previous Close
$2.46
52W Range
$1.60 - $5.88
50D Avg
$3.72
200D Avg
$2.83
Market Cap
$96.96M
Avg Vol (3M)
$263.63K
Beta
-0.40
Div Yield
-
GNLX Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TERN | Terns Pharmaceuticals, Inc. |
| CMPX | Compass Therapeutics, Inc. |
| DYAI | Dyadic International, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CELC | Celcuity Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| MNPR | Monopar Therapeutics Inc. |
| IVA | Inventiva S.A. |
| LRMR | Larimar Therapeutics, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| CGEM | Cullinan Oncology, Inc. |
| IKNA | Ikena Oncology, Inc. |
| CING | Cingulate Inc. |
| MLTX | MoonLake Immunotherapeutics |
| ABOS | Acumen Pharmaceuticals, Inc. |
| IMRX | Immuneering Corporation |